Neuroprotective Effects of Withaferin-A Nanoparticles on Scopolamine Rat Model of Alzheimer’s Disease
Madhu Subramanian★, Komala Munuswamy, Pandian Pitchaimuthu★ Corresponding author
- 1Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai Nagar, Chidambaram, Tamil Nadu, INDIA.
CORRESPONDENCE
Madhu Subramanian
Department of Pharmacy, Faculty, and Technology, Annamalai University, Annamalai Nagar-608002, Chidambaram, Tamil Nadu, INDIA.
Received: 30-09-2022; Revised: 23-02-2023; Accepted: 08-06-2023.
Volume 57, Issue 3S · pp. s620–s625 · PUBLISHED 2023 · DOI: 10.5530/ijper.57.3s.70
ABSTRACT
Background: Alzheimer's Disease (AD) suffers from dementia more often in 65-year or older patients. Symptoms of AD's are linked to disease-causing neurons, and current pharmacological therapies inadequately regulate deadly outcomes. Withania somnifera (L), has been contributing as a traditional multifunctional herb with a wide variety of health benefits. Materials and Methods: This research examined the importance of Withaferin A nanoparticles against scopolamine induced neuron loss (Impair on memory). Five groups of 6 rats weighing 150-200 g were randomly split. Negative and positive control animals received 2mL/kg saline solution in groups 1 and 2. 3^rd and 4^th group received 5mg/kg of pure Withaferin-A and Withaferin-A nanoformulation. Group 5 received 10 mg/kg of tacrine as a normal medication. Except for group 1, all other groups were induced 30 min after drug administration with 1mg/kg scopolamine. EPM was used to understand the behavioral parameters. Results: Inflexion ratios of 1.1 and 1.3 were seen in groups treated with Withaferin-A nanoparticles and the conventional medication. AchE, MDA, GSH reductase were also measured. Compared to the pure drug, Withaferin-A nanoparticles exhibited substantial activity. Withaferin-A exhibits an anti-amnesic effect similar to tacrine at a specific level. Conclusion: Withaferin-A nanoparticles may help neurodegenerative disease. To establish the formulation as a standard AD's treatment, pharmacokinetic aspects should be explored.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Subramanian, M., Munuswamy, K., & Pitchaimuthu, P. (2023). Neuroprotective Effects of Withaferin-A Nanoparticles on Scopolamine Rat Model of Alzheimer’s Disease. Indian Journal of Pharmaceutical Education and Research, 57(3S), s620–s625. https://doi.org/10.5530/ijper.57.3s.70